Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | BLM | P54132 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | XBP1 | P17861 | 1/20 | 0.46 |
| ▸ | UGCG | Q16739 | 1/20 | 0.44 |
| ▸ | KDM4C | Q9H3R0 | 3/20 | 0.44 |
| ▸ | KDM5A | P29375 | 2/20 | 0.44 |
| ▸ | KDM5B | Q9UGL1 | 2/20 | 0.44 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14356154 | 0.91 | MTNR1B (0.47) | TSHRBLMPDPK1 | |
| SCHEMBL9683763 | 0.83 | BLM (0.50) | TSHRBLMALDH1A1HTTXBP1 | |
| SCHEMBL3590904 | 0.81 | FFAR1 (0.52) | TSHRBLMALDH1A1HTTXBP1 | |
| SCHEMBL1568052 | 0.81 | BLM (0.51) | TSHRBLMALDH1A1HTTXBP1 | |
| SCHEMBL30301824 | 0.81 | FFAR1 (0.52) | TSHRBLMALDH1A1HTTXBP1 | |
| SCHEMBL10584761 | 0.80 | TSHR (0.50) | TSHRBLMALDH1A1HTTXBP1 | |
| SCHEMBL1725811 | 0.80 | BLM (0.50) | TSHRBLMALDH1A1HTTXBP1 | |
| SCHEMBL30572310 | 0.80 | BLM (0.50) | TSHRBLMALDH1A1HTTXBP1 | |
| SCHEMBL7038866 | 0.79 | HAO1 (0.53) | TSHRBLMALDH1A1HTTXBP1 | |
| SCHEMBL14632819 | 0.78 | CYP19A1 (0.45) | ALDH1A1HTTXBP1PDPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8357368-B2 | Methods of treating pancreatic or liver cancer using hedgehog antagonists | CURIS, INC. (US) | 2013-01-22 | — | — | US | disclosed |
| US-8168178-B2 | Methods and compositions for regulating lymphocyte activity | CURIS, INC. (US) | 2012-05-01 | — | — | US | disclosed |
| US-20120076996-A1 | RESIST COMPOSITION, RESIST FILM THEREFROM AND METHOD OF FORMING PATTERN THEREWITH | FUJIFILM CORPORATION (JP) | 2012-03-29 | — | — | US | disclosed |
| US-20110008333-A1 | METHODS OF INHIBITING UNWANTED CELL PROLIFERATION USING HEDGEHOG ANTAGONISTS | CURIS, INC. (US) | 2011-01-13 | — | — | US | disclosed |
| US-20100183560-A1 | Angiogenesis-modulating compositions and uses | CURIS, INC. (US) | 2010-07-22 | — | — | US | disclosed |
| US-7708998-B2 | Methods of inhibiting unwanted cell proliferation using hedgehog antagonists | CURIS, INC. (US) | 2010-05-04 | — | — | US | disclosed |
| US-7498304-B2 | Angiogenesis-modulating compositions and uses | CURIS, INC. (US) | 2009-03-03 | — | — | US | disclosed |
| US-20070021493-A1 | Mediators of hedgehog signaling pathways, compositions and uses related thereto | CURIS, INC. (US) | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021493-A1 | Mediators of hedgehog signaling pathways, compositions and uses related thereto | SHH, SMO, GLI1 | TSHR 1037/4885BLM 4026/4885ALDH1A1 4299/4885 |
| US-20110008333-A1 | METHODS OF INHIBITING UNWANTED CELL PROLIFERATION USING HEDGEHOG ANTAGONISTS | GLI1, SHH, SMO | TSHR 3027/4885BLM 4497/4885ALDH1A1 2236/4885 |
| US-20100183560-A1 | Angiogenesis-modulating compositions and uses | SHH, TEK, SMO | TSHR 2816/4885BLM 3735/4885ALDH1A1 1662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.